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Objective: The aim of this study was to characterize the SCN1A mutation spectrum in Korean patients
with Dravet syndrome.
Methods: Twenty-nine patients diagnosed with Dravet syndrome at the Seoul National University
Children’s Hospital were included in the study. Direct sequencing and multiplex ligation-dependent
probe ampliﬁcation (MLPA) were used to identify SCN1A mutations. Mutations were classiﬁed as either
truncation (nonsense and frameshift) or missense mutations.
Results: Nineteen pathogenic mutations (19/29; 66%) and three unclassiﬁed variants were identiﬁed.
One large deletion mutation spanning exons 1–20 was detected using MLPA. Fifteen of these 19 SCN1A
mutations were novel. Eleven mutations were classiﬁed as truncations (seven frameshift and four
nonsense mutations) and seven were classiﬁed as missense mutations. Truncating mutations spanned
the whole span of subunits of the SCN1A protein, whereas all missense mutations were localized at
either the voltage sensor (S4) or the ion pore (S5–S6) regions. Analysis according to clinical phenotype
revealed that SCN1A mutations were more frequent in the classic group than in the borderline group (78%
vs. 45%).
Conclusions: SCN1A mutational analysis of Korean Dravet syndrome patients resulted in the
identiﬁcation of 15 novel mutations, which could expand the spectrum of SCN1A mutations and
conﬁrms the current understanding of genotype–phenotype correlations.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Dravet syndrome (OMIM 607208) is an epileptic encephalop-
athy with typical clinical features, including seizure onset at
infancy, prolonged convulsive seizures usually triggered by fever,
later occurrence of polymorphic afebrile seizures, ataxia, cogni-
tive decline, and medical intractability.1 Since SCN1A was
identiﬁed as a major causative gene for Dravet syndrome, more
than 600 SCN1A mutations relevant to the disease have been
reported.2,3 In addition, animal models of SCN1A mutants
recapitulate the human disease successfully, demonstrating that
interneurons are the cellular substrate of Dravet syndrome, which
results in decreased inhibition in the presence of SCN1A* Corresponding author at: Department of Pediatrics, Seoul National University
College of Medicine, Pediatric Clinical Neuroscience Center, Seoul National
University Children’s Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic
of Korea. Tel.: +82 2 2072 3367; fax: +82 2 743 3455.
E-mail address: pednr@plaza.snu.ac.kr (K.J. Kim).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.08.002mutation.4,5 Truncating (nonsense and frameshift) and missense
mutations are the major mutation types in Dravet syndrome and
their relative frequency in patients with this disease was
estimated as being roughly similar to that reported in the large
SCN1A database.5 Loss of function was postulated as the
mechanism underlying truncating mutations in SCN1A, whereas
missense mutations may involve more complex mechanisms and
are possibly affected by other modiﬁer genes or environmental
factors.6 Recent reports have provided additional evidence that
supports this concept: ﬁrst, several genetic modiﬁers, such as
SCN8A, SCN9A, and CACNB4, have been described7–9; second, the
presence of mosaicism of truncating mutations in parents is
responsible for a milder phenotype and for the familial occurrence
of Dravet syndrome10; third, missense mutations in cases with
severe phenotype are clustered in the voltage sensor and ion pore
regions of SCN1A.11,12
In the present study, an SCN1A mutational analysis was
conducted in 29 Korean patients with Dravet syndrome and their
phenotypic variability was evaluated according to mutation type
and location in the subunits of the protein.vier Ltd. All rights reserved.
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2.1. Patients and clinical data
The Institutional Review Board of the Seoul National University
Hospital approved the study protocol. The study subjects were 29
patients diagnosed and followed at the Seoul National University
Children’s Hospital. The inclusion criteria for Dravet syndrome were
those described in a previous study13: normal development before
seizure onset, onset of the seizures before 1 year of age, seizures
mainly triggered by fever, prolonged convulsive seizures (>15 min),
later occurrence of seizures of various types, and later cognitive
regression. A diagnosis of classic Dravet syndrome was established if
either myoclonic or atypical absence seizures was present. Seizure
type was determined based either on description provided by the
parents or on video electroencephalographic  (EEG) monitoring
results. Myoclonic seizures detected using video EEG monitoring
were further classiﬁed into overt or subtle myoclonic types. Subtle
myoclonic seizures consist of brief subtle successive myoclonic
twitching including rhythmic retropulsion of the head accompanied
by irregular generalized spike waves of brief duration (2–3 s). These
subtle myoclonic seizures cannot be clearly differentiated from
atypicalabsenceseizures,assuggestedbyOguniet al.14Familyhistory
of febrile seizures or epilepsy in ﬁrst- or second-degree relatives was
investigated. Ruﬁnamide was administered  to ﬁve selected patients.
In these patients, all seizures were intractable to multiple (3)
antiepileptic drugs. Baseline seizure frequency was counted over a
period of 1 month before ruﬁnamide administration. Treatment
response was estimated based on seizure frequency reduction
compared with the baseline at 3 months after the treatment.
2.2. SCN1A mutational analysis
2.2.1. Direct sequencing
After obtaining informed consent from the parents of patients,
genomic DNA was extracted from peripheral blood leukocytesTable 1
Mutation and unclassiﬁed variant proﬁles of 22 patients.
Patient
number
Phenotype cDNA Protein Subunit
Truncation mutations
8 Classic c.7C>T p.Gln3X N-termi
19 Borderline c.1630delA p.Thr544HisfsX14 DI-DII 
6 Classic c.2088_2091delTTTC p.Ser696SerfsX8 DI-DII 
2 Classic c.2593C>T p.Arg865X DII S4 
3 Classic c.3160C>T p.Gln1036X DII-DIII 
20 Borderline c.3384delC p.Asn1128LysfsX18 DII-DIII 
7 Classic c.4127_4128delGT p.Cys1376TyrfsX2 DIII S5 
1 Classic c.4296delA p.Lys1432LysfsX6 DIII S5–
5 Classic c.4488delA p.Asn1554LysfsX5 DIII-DIV
9 Classic c.4662delC p.Asn1554LysfsX4 DIV S1 
4 Classic c.4906C>T p.Arg1636X DIV S4 
Missense mutations
10 Classic c.1177C>T p.Arg393Cys DI S5–S
14 Classic c.1187G>A p.Gly396Glu DI S5–S
12 Classic c.2854T>C p.Trp952Arg DII S5–S
21 Borderline c.3946A>T p.Arg1316Trp DIII S4 
22 Borderline c.3968C>G p.Pro1323Arg DIII S4 
13 Classic c.4216G>A p.Ala1406Thr DIII S5–
11 Classic c.5029C>T p.Leu1677Phe DIV S5 
Large deletion mutation
23 Borderline Exon 1–20 deletion 
Unclassiﬁed or undetermined variants
24 Borderline c.602+5delG 
26 Borderline c.4723C>T p.Arg1575Cys DIV S2 
25 Borderline c.4284+4A>T 
MAE, myoclonic astatic epilepsy.
a Elder sister of the patient had childhood absence epilepsy but did not carry the m
b Mosaicism of the mutation identiﬁed in the patient was suspected in the patient’susing a QIAamp1 DNA Blood Midi Kit, according to the manufac-
turers instructions (Qiagen, Valencia, CA, USA). Direct sequencing of
all coding exons and ﬂanking intronic sequences of the SCN1A gene
was performed using primer pairs designed by the authors (available
upon request). Polymerase chain reaction ampliﬁcation was
performed in a thermal cycler (Model 9700; Applied Biosystems,
Foster City, CA, USA) and cycle sequencing was performed on an ABI
Prism 3730xl DNA Analyzer using the BigDye Terminator Sequenc-
ing Ready Reaction Kit (Applied Biosystems). Sequence variations
were analyzed via comparison with the wild-type sequence
(transcript reference AB093548). The signiﬁcance of novel missense
variations was evaluated using the following methods: (1) allele
frequencies were screened in 100 ethnically matched normal
subjects; and (2) segregation patterns were analyzed among the
family members available. All candidate variants were searched in
the SCN1A variant database, to conﬁrm their novelty.3
2.2.2. Multiple ligation-dependent probe ampliﬁcation (MLPA)
MLPA analysis was performed using the SALSA MLPA kit P137-
A2 SCN1A (MRC Holland, Amsterdam, the Netherlands), according
to the manufacturers instructions. The MLPA samples consisted of
50–100 ng of genomic DNA. Ligation and ampliﬁcation were
performed using a PTC-200 thermal cycler (MJ Research, Waltham,
MA, USA). All ampliﬁed fragments were separated using capillary
electrophoresis on an ABI 3130xl Genetic Analyzer (Applied
Biosystems). The area under the peak for each ampliﬁed fragment
was measured and normalized to the peak areas of normal control
individuals using the GeneMarker software, version 1.6 (Soft-
Genetics, State College, PA, USA). The reference range was set at
0.75–1.3.
2.2.3. In silico analysis
Mutational properties of intronic variations were predicted
using automated splicing mutation analysis,15 which is a web-
oriented tool based on information theory (http://splice.cmh.
edu). location Family study Previous report 100 normal controls
nal De novo Dravet syndrome Not evaluated
De novo Novel Not evaluated
De novo Novel Not evaluated
Not available Dravet syndrome Not evaluated
De novoa Novel Not evaluated
De novo Novel Not evaluated
De novo Novel Not evaluated
S6 De novob Novel Not evaluated
 De novo Novel Not evaluated
De novo Novel Not evaluated
De novo Novel Not evaluated
6 Not available Dravet syndrome, MAE Not evaluated
6 De novo Novel Not found
6 De novo Novel Not found
De novo Novel Not found
De novo Novel Not found
S6 Father (+) Novel Not found
Not available Dravet syndrome Not evaluated
Not available Novel Not evaluated
De novo Novel Not found
Mother (+) Rasmussen encephalitis Not found
De novo Novel Not found
utation identiﬁed in the patient.
 father, who experienced several febrile seizures in his childhood.
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3.1. SCN1A mutational analysis of 29 patients with Dravet syndrome
Direct sequencing of SCN1A in 29 patients with Dravet
syndrome revealed the presence of 11 truncating mutations (four
nonsense and seven short deletion mutations ranging from one to
four base pairs), seven missense mutations, and three unclassiﬁed
variants (Table 1). One large deletion mutation spanning exons 1–
20 was identiﬁed using MLPA. Thus, 19 SCN1A mutations, including
15 novel mutations, were conﬁrmed (19/29; 66%). Truncating
mutations spanned the whole span of subunits of the SCN1A
protein, whereas all missense mutations localized to either the
voltage sensor (S4) or the ion pore (S5–S6) regions. Family studies
revealed that most of the mutations occurred de novo (14 out of 17
mutations tested). Automated splicing mutation analysis predicted
that two novel intronic variants (c.602+5delG and c.4284+4A>T)
caused a leaky splice site (Supplementary Figs. 1 and 2). However,
they were not classiﬁed as pathogenic mutations because
conﬁrmatory tests were not performed. One missense variant
(p.Arg1575Cys) was also classiﬁed as undetermined because of the
conﬂicting results of previous reports.13,16
3.2. Clinical features according to SCN1A mutation types
The phenotypes of the 29 patients were classiﬁed as either
classic or borderline, according to the criteria described in Section
2. The SCN1A mutation status (truncating or missense), seizure
onset, presence of myoclonic/absence seizures, video EEG moni-
toring results, family history, and ruﬁnamide treatment for these
patients are summarized in Table 2. SCN1A mutations were more
frequent in the classic group than in the borderline group (78% vs.
45%). Most of the truncating mutations (9/11) were found in the
classic group. Video EEG monitoring was performed in 15 patients.Table 2
Clinical features and genotype–phenotype correlations of 29 patients.
Patient number Phenotype SCN1A mutation Onset
(months)
Last follow-up (yea
1 Classic Truncation 5 1.3 
2 Classic Truncation 4 9.8 
3 Classic Truncation 8 5.0 
4 Classic Truncation 3 4.1 
5 Classic Truncation 6 3.1 
6 Classic Truncation 3 11.1 
7 Classic Truncation 3 2.5 
8 Classic Truncation 5 7.6 
9 Classic Truncation 2 1.5 
10 Classic Missense 3 14.4 
11 Classic Missense 4 1.6 
12 Classic Missense 7 2.8 
13 Classic Missense 9 3.0 
14 Classic Missense 3 1.9 
15 Classic Unclassiﬁed 4 12 
16 Classic Negative 8 15.6 
17 Classic Negative 11 11.1 
18 Classic Negative 10 2.9 
19 Borderline Truncation 6 2.1 
20 Borderline Truncation 7 2.5 
21 Borderline Missense 6 1.8 
22 Borderline Missense 9 3.3 
23 Borderline Large deletion 3 8.6 
24 Borderline Unclassiﬁed 5 4.8 
25 Borderline Unclassiﬁed 6 2.4 
26 Borderline Unclassiﬁed 9 1.9 
27 Borderline Negative 4 2.8 
28 Borderline Negative 6 1.9 
29 Borderline Negative 6 6.5 
GTC, generalized tonic–clonic seizure; SPS, simple partial seizure; CPS, complex partial s
absence epilepsy.Various seizure types were observed during the monitoring, with
subtle myoclonic seizure identiﬁed most frequently (seven
patients). Family history of febrile seizure or epilepsy was reported
in six families (6/29; 21%). The missense mutation detected in
patient 13 was also found in her father, who experienced several
febrile seizures in early childhood and generalized tonic–clonic
seizures during adolescence (Fig. 1A). The parents of two patients
with truncating mutations (patients 1 and 18) were mildly
affected. A mosaic state of the truncating mutation was suspected
in the father of patient 1 (Fig. 1B), although a conﬁrmatory test was
not performed. Patient 3, who harbored a truncating mutation, had
a sister affected with childhood absence epilepsy, although the
sister did not carry an SCN1A mutation (Fig. 1C). Seizure reduction
was observed in one patient among the ﬁve patients that received
ruﬁnamide treatment (Table 3). Although no speciﬁc acute adverse
events occurred, three patients discontinued the treatment
because of aggravation of myoclonic or generalized tonic–clonic
seizures.
4. Discussion
Although the SCN1A mutation detection rate in patients with
Dravet syndrome was below 50% in one previous study,17 recent
studies reported a uniform detection rate, ranging from 70% to
80%.13,18,19 Some authors speculated that this discrepancy may
have stemmed from the use of different inclusion criteria,13
although most studies reported using criteria adapted from those
proposed by the International League Against Epilepsy (2001). The
diagnosis of classic Dravet syndrome is sometimes difﬁcult in
young patients, as characteristic features, such as EEG changes,
seizure evolution, psychomotor regression, and presence of ataxia,
require a longer period of clinical observation. In addition, the
deﬁnition of borderline cases may be more problematic. Consid-
ering this limitation in deﬁning the diagnosis of study subjects, wers) Myoclonic/atypical
absence seizure
Video EEG
monitoring
Family
history
Ruﬁnamide
+/+ Subtle myoclonic Father FS 
+/ GTC, myoclonic, CPS – +
+/+ Subtle myoclonic Sister CAE 
+/ Subtle myoclonic – +
+/+ Subtle myoclonic – 
+/ GTC, myoclonic, SPS – 
+/ – 
+/+ Myoclonic Uncle FS +
+/ – 
+/+ – +
+/ – 
/+ CPS, atypical absence – 
+/+ Subtle myoclonic Father IGE 
+/+ Subtle myoclonic – 
/+ Atypical absence – 
+/ – +
+/ – 
+/ Subtle myoclonic Uncle FS 
/ Mother FS 
/ – 
/ – 
/ CPS – 
/ – 
/ – 
/ GTC – 
/ – 
/ – 
/ –
/ GTC –
eizure; IGE, idiopathic generalized epilepsy; FS, febrile seizure; and CAE, childhood
Fig. 1. Family study of three patients with novel SCN1A mutations. (A) c.4216G>A (p.Ala1406Thr) mutation in patient 13. The father, who exhibited clinical features of
idiopathic generalized epilepsy, harbored the same mutation. (B) c.4296delA (p.Phe1432LeufsX6) mutation in patient 1. The mildly affected father may be a mosaic for the
same mutation found in the patient. (C) c.3160C>T (p.Gln1036X) mutation in patient 3. The elder sister was diagnosed with childhood absence epilepsy; however, she did not
carry a mutation in SCN1A.
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Table 3
Clinical features of ﬁve patients treated with ruﬁnamide.
Patient
number
Phenotype SCN1A
mutation
type
Seizure
aggravation
by previous
AEDs
Main seizure
types at
RFN start
Concomitant
AEDs at RFN
start
Age of RFN
start (years)
RFN dose
(mg/day/mg/kg/day)
Response
10 Classic Missense Not deﬁnite GTC TPM, LEV, CLB 14.1 400/8 Seizure reduction of
50–99%
2 Classic Missense OXC GTC, absence VPA, LTG, LEV 9.3 600/23 No change
4 Classic Truncation Not deﬁnite GTC LEV, CNZ, LTG 3.6 200/16 Seizure aggravation
8 Classic Truncation Not deﬁnite GTC, myoclonic ZNS, CLB, LTG 7.1 800/40 Seizure (GTC + myoclonic)
aggravation
16 Classic Negative Not deﬁnite GTC, myoclonic VPA, LTG 15.1 800/16 Myoclonic seizure aggravation
AED, antiepileptic drug; RFN, ruﬁnamide; OXC, oxcarbazepine; TPM, topiramate; LEV, levetiracetam, CLB, clobazam; VPA, valproic acid; LTG, lamotrigine; CNZ, clonazepam;
ZNS, zonisamide; and GTC, generalized tonic–clonic seizure.
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a large patient group,13 which included patients with various
clinical presentations that shared the core features and focused on
initial manifestations. Using these criteria, we obtained a mutation
detection rate (66%) that was slightly lower than that reported in
other recent studies. As two of three unclassiﬁed variants were
novel and predicted to cause aberrant splicing based on in silico
analysis, mutation detection rate would be over 70% when
including these variants. A prospectively designed study with a
genetic analysis performed in the earlier disease stage may be
required to avoid possible selection or ascertainment biases.
Furthermore, the accurate timing of SCN1A testing could also be
determined using this design, which could be helpful for the
management and genetic counseling of the disease.
Among the 19 pathogenic mutations detected, 15 mutations
had not been reported in the literature or in the SCN1A variant
database.3 In our study, the proportion of truncating mutations
among the point mutations (11/18; 61%) was slightly higher than
the proportion of missense mutations (7/18; 39%). Regarding the
location of missense mutations in the subunits of the protein, all
seven missense mutations were located in the S4 or S5–S6 regions,
which constitute the voltage sensor and ion pore regions,
respectively. These genotype–phenotype correlations appear to
be consistent with the results of recent studies.12,19
Somatic mosaicism may explain the variable phenotypes
associated with truncating mutations.10 The father of patient 1
experienced several febrile seizures in his early childhood. Somatic
mosaicism of the same frameshift mutation identiﬁed in patient 1
was suspected on the electropherogram of the father, although exact
quantiﬁcation was not performed. The mother of patient 18 had a
history of febrile seizures and may be in a similar situation regarding
somatic mosaicism; however, conﬁrming this status would also
require further testing. Although this mechanism may be a more
frequent cause of familial cases or of mild phenotypes than thought
previously, the need for additional conﬁrmatory procedures is the
main obstacle to conducting more extensive research. Next-
generation sequencing technology could be used for this purpose,
as quantiﬁcation of variants is feasible using a single platform.20
Among the three unclassiﬁed or undetermined variants detected
here, the pathogenicity of the p.Arg1575Cys variant was interpreted
differentially in two previous studies. This variant was reported as a
pathogenic mutation in a patient with Rasmussen encephalitis, based
on an in vitro functional study.16 However, Depienne et al. suggested
that this variant may be a rare polymorphism that is unrelated to
Dravet syndrome.13 The index case in the study of Depienne et al.
harbored another nonsense mutation, in addition to p.Arg1575Cys.
Moreover, p.Arg1575Cys was found in his asymptomatic mother,
although this variant was not found in 100 Caucasian controls. In the
present study, this variant was also not found in 100 Korean controls,
but was found in the asymptomatic mother of the patient. Although
there was insufﬁcient evidence to ascertain the pathogenicity of thisvariant, the recurrence of rare neurological disorders, such as
Rasmussen encephalitis and Dravet syndrome, in different ethnic
groups (Caucasian and Korean populations) raises the suspicion that
this variant may be an incompletely penetrant pathogenic variant or a
susceptiblity allele acting in a polygenic manner. The presence of two
SCN1A pathogenic mutations in a single Dravet syndrome patient or
the presence of mildly affected transmitting parents has been
reported,13,19 suggesting the existence of modifying factors, espe-
cially in patients with missense mutations. The presence of additional
modifying factors could also be suspected in the case of patient 3,
whose elder sister was diagnosed with childhood absence epilepsy
and did not harbor the same SCN1A nonsense mutation. However,
despite the report of a few presumed genetic modiﬁers, the genes
involved as a whole and their complex interaction with SCN1A
remain poorly understood.
A recent study that evaluated the long-term efﬁcacy and
tolerability of ruﬁnamide treatment in patients with Dravet
syndrome reported a rather disappointing outcome.21 Both low
efﬁcacy and aggravation of seizures in a signiﬁcant proportion of
patients (30%) contributed to a low long-term retention rate of
only 5% after 34 months of treatment. The present study, although
based on the results obtained from a small number of patients, also
revealed that three out of ﬁve patients had seizure aggravation,
which could represent supporting evidence against the use of
ruﬁnamide in patients with Dravet syndrome.
This is the ﬁrst report discussing the SCN1A mutation spectrum
in Korean patients with Dravet syndrome. Genotype–phenotype
correlation was largely consistent with the previous studies of
individuals with European and Japanese ancestry. Although our
study presented conﬁrmatory results stemming partly from a
small cohort, the phenotypic variablity found within the affected
family members will be the subject of future research.
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